Immunology and inflammation Archives -

Roche deepens ties with Jnana with a second licensing deal

Phil Taylor financing, Immunology and inflammation, Jnana Therapeutics, neurology, Oncology, partnering, Roche 0 Comment

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to

Roche deepens ties with Jnana with a second licensing deal

https://pharmaphorum.com/news/roche-deepens-ties-with-jnana-with-a-second-licensing-deal/

News/ News/ News/ Oncology/ R&D

Galapagos’ new CEO Paul Stoffels wields axe in bid to go ‘forward, faster’

Phil Taylor Galapagos, Immunology and inflammation, Oncology, R&D 0 Comment

When long-serving Johnson & Johnson R&D chief Paul Stoffels cut short his retirement to take the helm at

Galapagos’ new CEO Paul Stoffels wields axe in bid to go ‘forward, faster’

https://pharmaphorum.com/news/galapagos-new-ceo-paul-stoffels-wields-axe-in-pursuit-of-growth/

News/ News/ R&D

Weak data for Fasenra undermine AZ’s ambitions for the drug

Phil Taylor AstraZeneca, Dupixent, eosinophilic oesophagitis, Fasenra, GlaxoSmithKline, Immunology and inflammation, Nucala, Regeneron, Sanofi 0 Comment

AstraZeneca’s IL-5 inhibitor Fasenra is already making blockbuster sales from its use in eosinophilic asthma, but the drugmaker’s

Weak data for Fasenra undermine AZ’s ambitions for the drug

https://pharmaphorum.com/news/weak-data-for-fasenra-undermine-azs-ambitions-for-the-drug/

News/ News/ R&D

Novo Nordisk grabs NASH drug from Ventus in $703m deal

Phil Taylor hepatology, Immunology and inflammation, licensing, NASH, NLRP3, Novo Nordisk, Ventus Therapeutics 0 Comment

Denmark’s Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus

Novo Nordisk grabs NASH drug from Ventus in $703m deal

https://pharmaphorum.com/news/novo-nordisk-grabs-nash-drug-from-ventus-in-703m-deal/

Boehringer Ingelheim, Biberach, Germany, February 2007

Market Access/ News/ News/ News/ Patients

Boehringer bags first approval for rare skin disease drug

Phil Taylor Boehringer Ingelheim, dermatology, Immunology and inflammation, rare disease, spesolimab, Spevigo 0 Comment

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening

Boehringer bags first approval for rare skin disease drug

https://pharmaphorum.com/news/boehringer-bags-first-approval-for-rare-skin-disease-drug/

News/ News/ R&D

BMS adds to IBD pipeline with $1.9bn GentiBio deal

Phil Taylor Bristol-Myers Squibb, deucravacitinib, GentiBio, Immunology and inflammation, inflammatory bowel disease, partnering, Treg, Zeposia 0 Comment

Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for

BMS adds to IBD pipeline with $1.9bn GentiBio deal

https://pharmaphorum.com/news/bms-adds-to-ibd-pipeline-with-1-9bn-gentibio-deal/

News/ News/ R&D

Gilead snaps up MiroBio and its checkpoint agonists for $405m

Phil Taylor AnaptysBio, Eli Lilly, Gilead Sciences, Immunology and inflammation, M&A, MiroBio 0 Comment

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a

Gilead snaps up MiroBio and its checkpoint agonists for $405m

https://pharmaphorum.com/news/gilead-snaps-up-mirobio-and-its-checkpoint-agonists-for-405m/

News/ News/ R&D

Amgen splashes out on ChemoCentryx and its blockbuster hopeful

Phil Taylor Amgen, ChemoCentryx, Immunology and inflammation, M&A, nephrology, Tavneos 0 Comment

Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in

Amgen splashes out on ChemoCentryx and its blockbuster hopeful

https://pharmaphorum.com/news/amgen-splashes-out-on-chemocentryx-and-its-blockbuster-hopeful/

News/ News/ R&D

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Phil Taylor China, Eli Lilly, financing, Genfleet Therapeutics, GlaxoSmithKline, Immunology and inflammation, Rigel Pharmaceuticals, RIPK1, Sanofi, Sironax 0 Comment

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire

Chinese biotech Sironax raises $200m for RIPK1 pipeline

https://pharmaphorum.com/news/chinese-biotech-sironax-raises-200m-for-ripk1-pipeline/

Trending

Immunology and inflammation

Login